Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
October 14, 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
October 11, 2024
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
October 2, 2024
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
September 30, 2024
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
September 23, 2024
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
June 13, 2024
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
May 30, 2024
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
May 8, 2024
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 17, 2024
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
April 10, 2024
Alterity Therapeutics Receives a $3.9 million Research & Development Tax Incentive Refund
March 26, 2024
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
February 20, 2024
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
February 7, 2024
Alterity Therapeutics Successfully Completes Securities Purchase Plan (SPP)
February 2, 2024
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
February 1, 2024
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
January 22, 2024
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
December 4, 2023
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
December 4, 2023
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
November 27, 2023
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
November 16, 2023
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
November 8, 2023
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
August 31, 2023
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
August 23, 2023
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
August 22, 2023
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
August 15, 2023
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
July 26, 2023
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
June 21, 2023
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
May 30, 2023
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
May 19, 2023
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
May 10, 2023
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
April 26, 2023
Alterity Therapeutics Enrols First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
April 4, 2023
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
March 16, 2023
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
March 14, 2023
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
March 8, 2023
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
February 16, 2023
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
January 30, 2023
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
January 25, 2023
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
January 9, 2023
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
January 3, 2023
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
December 29, 2022
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
November 7, 2022
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
October 26, 2022
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
October 13, 2022
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson’s Disease and Movement Disorders
September 26, 2022
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
September 20, 2022
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
August 25, 2022
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
July 6, 2022
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
June 23, 2022
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
June 14, 2022
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
June 2, 2022
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
May 26, 2022
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
April 27, 2022
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
April 7, 2022
Alterity Therapeutics to Participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum
March 15, 2022
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease
January 28, 2022
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s
January 6, 2022
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 5, 2022
First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
December 14, 2021
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
November 9, 2021
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
November 4, 2021
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
October 19, 2021
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
August 4, 2021
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s
July 1, 2021
Alterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference
June 16, 2021
Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference
March 10, 2021
Alterity to present at the 7th International Congress of Multiple System Atrophy
February 26, 2021
Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials
February 9, 2021
Alterity participates in world’s largest virtual healthcare conference JP Morgan
January 11, 2021
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
November 16, 2020
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
October 27, 2020
Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.
October 16, 2020
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
August 4, 2020
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
June 30, 2020
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
May 21, 2020
European Commission approves Orphan Designation for Alterity’s lead drug candidate
January 14, 2020
Alterity’s lead drug candidate receives positive opinion from European medical agency
November 18, 2019
Alterity Therapeutics to Present at the Janney Healthcare Conference in New York
September 9, 2019
Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial
July 29, 2019
Alterity Therapeutics commences US investor meetings following positive clinical data
May 13, 2019
Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting
May 6, 2019
Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting
May 3, 2019
Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana
December 27, 2018
PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders
July 8, 2018
First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases
July 3, 2018
Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases
June 13, 2018
Prana to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium in Hangzhou, China
March 15, 2018
PBT434 poster presented at the 6th International Multiple System Atrophy Conference
March 6, 2018
Prana meeting with investors at world’s largest healthcare conference in San Francisco
January 8, 2018
Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology
July 18, 2017
Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development
June 5, 2017
Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases
March 30, 2017
Prana provides regulatory update for PBT2 for the treatment of Huntington disease
November 2, 2016
New data from Reach2HD trial presented at American Neurological Association Annual Meeting
October 18, 2016
Prana’s Huntington Disease trial analysis to feature at global movement disorder conference
June 22, 2016
Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease
September 8, 2014
Prana Biotechnology announces top line results of Phase 2 IMAGINE trial of PBT2 in Alzheimer’s disease
March 31, 2014
Prana Biotechnology Presents to US Investors at 34th Cowen Healthcare Conference
March 4, 2014
Prana Biotechnology Investor Presentation and Audio Recording – Phase 2 HD trial
February 18, 2014
Prana Provides Update on IMAGINE Trial and Extension Trial for Alzheimer’s Disease
November 27, 2013
Prana prepares for next steps in the PBT2 development path to market and commercialization with key appointments strategy
October 6, 2013
FDA Approval to Commence Huntington’s Disease Clinical Trial Using Prana’s PBT2: Huntington Study Group appointed to coordinate the trial and start recruitment
July 17, 2013
Prana Comments on Nature Medicine, PNAS and Journal of Alzheimer’s Disease articles that highlight the Role of Metals in Neurological Diseases
July 17, 2013
PLoS ONE Journal Publishes Mechanistic Model of Alzheimer’s Disease Endorsing Prana’s PBT2
July 17, 2013
Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial
July 17, 2013
Prana Comments on Archives of Neurology Publication Which Highlights Critical Role of Brain Metals in Huntington Disease Progression: MGH team publishes data that supports the use of PBT2 in Huntington disease
July 17, 2013
Prana to Present at the UBS Australian Healthcare Conference in Sydney and the Australian Life Science Investment Showcase in New York
July 17, 2013
Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention: Prana’s ‘Reach2HD’ Phase II trial on track
July 17, 2013
ABC Radio Jon Faine Program features Prana IMAGINE trial for Alzheimer’s disease
July 17, 2013
Prana Provides Clinical Trials Update: Alzheimer’s and Huntington disease trials on track
July 17, 2013
Prana’s Parkinson’s drug meets Michael J. Fox Foundation development milestone – PBT434 advances through IND enabling studies
July 17, 2013
Prana Shows Significant Promise in the Fight Against Alzheimer’s Disease According to Experts at Celebration of Science Conference
July 17, 2013
Prana Receives Recommendation to Proceed with Alzheimer’s Clinical Trial from Data Safety Monitoring Board (DSMB)
July 17, 2013
Further Information – Prana’s PBT2 Clinical Trials Cited as Most Advanced in Addressing Neurodegeneration from the Metal Equilibrium Perspective
July 17, 2013
Prana Scientist to Participate in Webcast to Discuss Alzheimer’s Disease Therapeutics: Recent Setbacks and Emerging Technologies on Monday, October 1
July 17, 2013
Prana Provides Huntington Disease Trial Update in conjunction with the Huntington Study Group Annual Conference
July 17, 2013
Metal Hypothesis for Alzheimer’s, Huntington and other Neurodegenerative Diseases Declared Promising Therapeutic Strategy by Scientists at New York Academy of Sciences Symposium
July 17, 2013
Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MA
July 17, 2013
Prana Announces that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
July 17, 2013
Prana’s PBT434 Inhibits Accumulation of Parkinson’s protein and Subsequent Death of Brain Cells
July 17, 2013
Prana Details Data Showing that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
July 17, 2013
Prana presents new benchmark test to assess Huntington’s Disease patients in clinical trials
July 17, 2013
PBT434 drug candidate shows potential as “next-generation” disease-modifying treatment in Parkinson’s Disease
July 17, 2013
Prana Receives Approval For 12-Month Open Label Extension Study In Alzheimer’s Disease
July 17, 2013
Receive news from Alterity Therapeutics
